Ataxia-telangiectasia (A-T)

What is Ataxia-telangiectasia?

Ataxia-telangiectasia (A-T), also known as Louis-Bar syndrome, is a rare genetic disorder that affects multiple body systems, causing progressive movement problems, immune deficiency, and increased cancer risk. This autosomal recessive condition primarily affects the nervous system and immune system, typically appearing in early childhood when children begin walking. A-T affects approximately 1 in 40,000 to 100,000 births worldwide, making it one of the more common forms of hereditary ataxia. The condition is caused by mutations in the ATM gene, which plays a crucial role in DNA repair and cell cycle control.

Key statistics

Symptoms

Progressive cerebellar ataxia, telangiectasias, recurrent infections, growth delays, neurological deterioration, cancer predisposition, endocrine abnormalities, premature aging features.

The symptoms of A-T typically emerge in early childhood and progress over time. Cerebellar ataxia is often the first noticeable symptom, appearing when children begin walking. This causes unsteady gait, difficulty with coordination, and problems with balance that worsen over time.

Telangiectasias are small, dilated blood vessels that appear as red spider-like marks on the whites of the eyes and skin, typically developing between ages 3-6 years. These are often the first visible sign that leads to diagnosis.

Submit Your Paper

Immunodeficiency manifests as recurrent respiratory infections, including sinusitis, bronchitis, and pneumonia. Children may experience frequent ear infections and have difficulty fighting off common bacterial and viral infections.

Neurological symptoms progressively worsen and may include slurred speech (dysarthria), difficulty swallowing (dysphagia), involuntary muscle movements (chorea), and peripheral neuropathy. Many children eventually require wheelchairs for mobility.

Growth and development issues include short stature, delayed puberty, and failure to thrive. Some children may experience premature graying of hair and other signs of accelerated aging.

Cancer susceptibility significantly increases, particularly for lymphomas and leukemias, which develop in approximately 25-30% of individuals with A-T.

Causes and risk factors

Ataxia-telangiectasia is caused by mutations in the ATM gene (ataxia telangiectasia mutated), located on chromosome 11. The ATM gene produces a protein essential for DNA repair and cell cycle checkpoint control. When this gene is mutated, cells cannot properly repair DNA damage, leading to cell death and the various symptoms of A-T.

A-T follows an autosomal recessive inheritance pattern, meaning both parents must be carriers (having one copy of the mutated gene) for a child to be affected. When both parents are carriers, each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier, and a 25% chance of producing a child with normal genes.

Risk factors include having parents who are carriers of ATM mutations. Consanguineous marriages (between related individuals) increase the risk, as do certain population groups with higher carrier frequencies. No environmental or lifestyle factors are known to cause or increase the risk of A-T.

Prevention

As A-T is an inherited genetic condition, it cannot be prevented through lifestyle modifications or environmental changes. However, genetic counseling and testing offer important prevention strategies for families at risk.

Carrier testing can identify individuals who carry one copy of an ATM mutation. This is particularly important for family members of affected individuals. Prenatal testing through amniocentesis or chorionic villus sampling can diagnose A-T in a developing fetus when both parents are known carriers.

Preimplantation genetic diagnosis (PGD) during in vitro fertilization allows couples who are both carriers to select embryos without A-T for implantation. Population screening for carrier status is not routinely recommended due to the large number of possible ATM mutations and the condition’s rarity.

Complications

Without proper medical management, A-T can lead to severe complications affecting multiple organ systems. Progressive neurodegeneration eventually results in complete loss of mobility, with most individuals becoming wheelchair-bound by their teens.

Respiratory complications are among the most serious, as recurrent infections combined with swallowing difficulties can lead to aspiration pneumonia. Progressive lung disease may develop due to chronic infections and aspiration.

Cancer development poses a significant long-term risk, with lymphomas and leukemias being most common. The immune system progressively weakens, making infections increasingly difficult to treat and potentially life-threatening.

Endocrine complications may include diabetes mellitus and gonadal dysfunction. Progressive swallowing difficulties can lead to malnutrition and require feeding tube placement. Some individuals develop liver problems and kidney dysfunction over time.

Diagnosis

Diagnosis of A-T typically involves multiple clinical and laboratory findings. The characteristic combination of progressive ataxia beginning in early childhood, telangiectasias, and recurrent infections should prompt diagnostic testing.

Alpha-fetoprotein (AFP) levels are elevated in over 95% of individuals with A-T, making this a key screening test. Normal AFP levels in a child over 2 years old make A-T very unlikely.

Immune system evaluation often reveals low or absent immunoglobulin levels (particularly IgA and IgG2), reduced T-cell numbers, and poor vaccine responses.

Genetic testing for ATM mutations provides definitive diagnosis. However, since the ATM gene is very large with many possible mutations, comprehensive sequencing may be required.

Cellular studies can demonstrate increased radiation sensitivity and defective cell cycle checkpoints in cultured skin cells (fibroblasts).

Brain imaging with MRI typically shows cerebellar atrophy, which becomes more pronounced over time.

Chromosome analysis may reveal characteristic chromosome breaks and rearrangements, particularly involving chromosomes 7 and 14.

Treatment

Currently, no cure exists for A-T, and treatment focuses on managing symptoms and preventing complications. A multidisciplinary approach involving neurologists, immunologists, oncologists, and other specialists is essential.

Immunoglobulin replacement therapy with immunoglobulin (IVIG or subcutaneous immunoglobulin) helps prevent infections in patients with significant immunodeficiency.

Respiratory care includes aggressive treatment of infections with appropriate antibiotics, chest physiotherapy, and sometimes prophylactic antibiotics. Azithromycin may be used for its anti-inflammatory properties.

Physical and occupational therapy helps maintain mobility and function as long as possible. Speech therapy addresses swallowing difficulties and communication problems.

Antioxidant supplementation with compounds like coenzyme Q10 and vitamin E is being studied, though benefits remain unclear.

Cancer surveillance involves regular monitoring with blood tests and imaging to detect malignancies early when treatment is most effective.

Supportive care may include feeding tubes for nutrition, assistive devices for mobility, and management of diabetes or other endocrine problems.

Prognosis

The prognosis for A-T varies significantly among individuals, but the condition is generally progressive. Life expectancy has improved with better medical management, and many individuals now survive into their 20s, 30s, and beyond.

Factors affecting prognosis include the severity of neurological progression, frequency and severity of infections, cancer development, and access to comprehensive medical care. Early diagnosis and proactive management of complications significantly improve outcomes.

Quality of life can be maintained for many years with appropriate support, assistive technologies, and adaptive strategies. However, the progressive nature of the neurological symptoms means most individuals will eventually require full-time care.

Cancer development remains a major prognostic factor, as lymphomas and leukemias can be aggressive in A-T patients and may not respond as well to standard treatments due to their DNA repair defects.

Quality of life

Living with A-T requires significant adaptations, but many individuals maintain good quality of life with proper support. Educational accommodations help children continue learning despite progressive physical limitations.

Adaptive equipment including wheelchairs, communication devices, and modified computers enable continued participation in activities and social interactions. Home modifications such as ramps, accessible bathrooms, and safety equipment improve independence and safety.

Nutrition management becomes increasingly important as swallowing difficulties develop. Working with dietitians and speech therapists helps maintain adequate nutrition while minimizing aspiration risk.

Mental health support is crucial for both patients and families coping with this progressive condition. Counseling, support groups, and connections with other A-T families provide emotional support and practical advice.

Regular exercise within physical limitations helps maintain strength and cardiovascular health. Swimming is often well-tolerated and beneficial for maintaining fitness.

Pregnancy and fertility

Fertility may be affected in some individuals with A-T due to endocrine dysfunction and gonadal abnormalities. Women with A-T who become pregnant require high-risk obstetric care due to potential complications.

Genetic counseling is essential for individuals with A-T who wish to have children, as each child would be a carrier of an ATM mutation. If the partner is also a carrier, each pregnancy would have a 25% chance of producing an affected child.

Prenatal care must account for the mother’s immunodeficiency, potential respiratory problems, and other A-T-related complications. Close monitoring throughout pregnancy and delivery planning with experienced specialists is crucial.

Children

A-T primarily affects children, with symptoms typically appearing in early childhood. Early intervention services including physical therapy, occupational therapy, and speech therapy are crucial for maximizing development and function.

Educational planning should begin early, with anticipation of progressive physical limitations. Many children with A-T are intellectually normal or only mildly affected, so academic accommodations focus on physical access and communication needs.

Infection prevention is paramount in childhood, including prompt treatment of illnesses, appropriate vaccinations (avoiding live vaccines), and sometimes prophylactic antibiotics during high-risk periods.

Family support and sibling counseling help the entire family cope with the challenges of A-T while maintaining as normal a childhood as possible for the affected child.

When to see a doctor

Urgent medical attention is needed for signs of serious infection, including high fever, difficulty breathing, persistent cough, or changes in mental status. Any signs of neurological deterioration or new neurological symptoms warrant prompt evaluation.

Routine medical care should include regular monitoring by the multidisciplinary A-T team, typically every 3-6 months. Annual cancer screening, respiratory function tests, and immune system monitoring are essential.

Parents should seek evaluation if a young child shows persistent coordination problems, frequent infections, or unusual blood vessel markings on the eyes or skin. Early diagnosis enables better management and family planning.

Regional context

Limited data exists on A-T prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or the broader Eastern Mediterranean. Some populations may have higher carrier frequencies due to founder effects or consanguineous marriages.

Genetic studies in various Middle Eastern and Mediterranean populations have identified specific ATM mutations that may be more common in certain ethnic groups. Regional medical centers increasingly recognize A-T and offer appropriate testing and management.

We invite healthcare providers and researchers in the Caucasus and Eastern Mediterranean regions to contribute data on A-T prevalence and characteristics to the Global Medical Journal to better understand regional patterns.

Research and clinical trials

Current research focuses on several promising areas including antioxidant therapies, stem cell treatments, and gene therapy approaches. Clinical trials are investigating compounds that might slow neurodegeneration or improve immune function.

Research into cancer prevention and treatment specifically for A-T patients is ongoing, as standard cancer treatments may be less effective or more toxic in individuals with DNA repair defects.

Studies of ATM function continue to reveal new potential therapeutic targets. Some research focuses on drugs that might partially restore ATM function or compensate for its loss.

Families can search for current clinical trials at ClinicalTrials.gov using the search term “ataxia telangiectasia.” The A-T Children’s Project maintains updated information about research opportunities and actively funds promising research initiatives.

Frequently asked questions

Is ataxia-telangiectasia contagious?

No, A-T is a genetic condition present from birth and cannot be transmitted between people through contact. However, individuals with A-T are more susceptible to infections due to their compromised immune systems.

Can A-T symptoms be reversed or cured?

Currently, no cure exists for A-T, and the neurological symptoms are generally progressive and irreversible. However, early intervention and supportive care can significantly slow progression and improve quality of life.

How is A-T different from other types of ataxia?

A-T is distinguished by its combination of ataxia, telangiectasias, immunodeficiency, and cancer predisposition. The elevated AFP levels and characteristic immune abnormalities help differentiate it from other hereditary ataxias.

Should family members of A-T patients be tested?

Yes, siblings and parents should consider genetic counseling and carrier testing. This information is important for family planning and identifying other at-risk relatives who might benefit from testing.

Can people with A-T receive vaccines?

Most vaccines are safe and recommended for people with A-T, though live vaccines should be avoided due to immunodeficiency. Vaccine responses may be reduced, so additional monitoring for protective immunity may be necessary.

Support and resources

A-T Children’s Project (https://www.atcp.org/) – Leading patient organization providing research funding, family support, and comprehensive information about A-T.

National Organization for Rare Disorders (NORD) (https://rarediseases.org/) – Comprehensive rare disease information and patient advocacy.

Orphanet (https://www.orpha.net/) – European rare disease database with detailed medical information.

EURORDIS (https://www.eurordis.org/) – European rare disease patient advocacy organization.

Ataxia UK (https://www.ataxia.org.uk/) – Support for individuals with ataxia and their families.

International Ataxia Awareness Day (September 25) – Annual awareness campaign for all types of ataxia.

Related conditions

Friedreich ataxia – Another hereditary ataxia with different genetic cause and features

Spinocerebellar ataxia – Group of hereditary ataxias with adult onset

Primary immunodeficiency – Various genetic conditions causing immune system dysfunction

Nijmegen breakage syndrome – Another DNA repair disorder with similar features

DNA repair disorders – Group of conditions affecting cellular DNA repair mechanisms

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, A-T Children’s Project, International A-T research literature. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.